12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DCVax-L: Phase III ongoing

Northwest Biotherapeutics said the U.K.'s National Institute for Health Research (NIHR) "adopted" the biotech's double-blind, international Phase III trial of DCVax-L in up to 300 patients with newly diagnosed GBM as a national priority trial in the U.K. According to the company, priority trials are monitored by...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >